Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
14.45
-0.27 (-1.83%)
At close: Apr 3, 2025, 4:00 PM
14.43
-0.02 (-0.14%)
After-hours: Apr 3, 2025, 5:09 PM EDT

Company Description

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally.

The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis.

Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio.

The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands.

In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss.

The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions.

Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Organon & Co.
Organon & Co. logo
Country United States
Founded 1923
Industry Drug Manufacturers - General
Sector Healthcare
Employees 10,000
CEO Kevin Ali

Contact Details

Address:
30 Hudson Street, Floor 33
Jersey City, New Jersey 07302
United States
Phone (551) 430-6900
Website organon.com

Stock Details

Ticker Symbol OGN
Exchange NYSE
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001821825
CUSIP Number 68622V106
ISIN Number US68622V1061
Employer ID 46-4838035
SIC Code 2834

Key Executives

Name Position
Kevin Ali Chief Executive Officer and Director
Matthew M. Walsh C.F.A. Executive Vice President and Chief Financial Officer
Kirke Weaver Executive Vice President, General Counsel and Corporate Secretary
Joseph T. Morrissey Jr. Executive Vice President and Head of Manufacturing and Supply
Jennifer Halchak Head of Investor Relations
Susan O'Neal Chief Ethics and Compliance Officer
Rebecca Lowell Edwards Chief Communications Officer
Daniel Karp Head of Corporate Development
Aaron Falcione Executive Vice President and Chief Human Resources Officer
Vittorio Nisita Executive Vice President and Head of Global Business Services

Latest SEC Filings

Date Type Title
Feb 28, 2025 10-K Annual Report
Feb 13, 2025 8-K Current Report
Jan 21, 2025 8-K Current Report
Dec 23, 2024 8-K Current Report
Dec 6, 2024 8-K Current Report
Nov 5, 2024 8-K Current Report
Nov 1, 2024 10-Q Quarterly Report
Oct 31, 2024 8-K Current Report
Sep 23, 2024 8-K Current Report
Aug 7, 2024 10-Q Quarterly Report